Literature DB >> 18417094

Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001).

H A Schmid1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18417094     DOI： 10.1016/j.ando.2008.02.020

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN： 0003-4266            Impact factor:   2.478


× No keyword cloud information.
  3 in total

1.  Correlation of monoclonal and polyclonal somatostatin receptor 5 antibodies in pancreatic neuroendocrine tumors.

Authors:  Daniel Kaemmerer; Amelie Lupp; Luisa Peter; Elke Fischer; Stefan Schulz; Günter Klöppel; Merten Hommann
Journal:  Int J Clin Exp Pathol       Date:  2012-11-20

2.  Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Authors:  Florian Pöll; Diana Lehmann; Susann Illing; Mihaela Ginj; Stefan Jacobs; Amelie Lupp; Ralf Stumm; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2010-01-05

3.  A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Authors:  Georg Golor; Ke Hu; Matthieu Ruffin; Alexandra Buchelt; Emmanuel Bouillaud; Yanfeng Wang; Mario Maldonado
Journal:  Drug Des Devel Ther       Date:  2012-04-19       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.